Real-world use of a hydrophilic curcumin-based oral formulation in the management of macular oedema: a collection of clinical experiences

Abstract

This is a collection of clinical experiences exploring the real-world effectiveness of a hydrophilic curcumin-based oral formulation (CHC, Diabec^®) in the management of macular oedema across diverse retinal conditions, including diabetic macular oedema, central serous chorioretinopathy, branch retinal vein occlusion and Irvine–Gass syndrome. Eight cases reported significant improvements in best-corrected visual acuity and central macular thickness, with complete resolution of oedema in some instances. CHC was well tolerated, with no adverse effects reported. These findings suggest that CHC is a safe and effective adjunct or standalone therapy for chronic or refractory macular oedema, enhancing anatomical and functional outcomes in real-world settings.